AMRX vs LGND

AMRX's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns about operational efficiency and profitability sustainability. The absence of an Altman Z-Score and a Debt/Equity ratio of 450.96 signal extreme leverage and potential distress risk, severely undermining financial stability. Despite strong revenue growth (11.5% YoY) and impressive earnings surprises (average +26.6% over last 4 quarters), the stock trades at a forward P/E of 10.12 but a trailing P/E of 53.77, suggesting overvaluation relative to current earnings. The lack of dividends, negative Price/Book, and bearish insider activity further erode investor confidence. The stock's 1-month decline of 19.5% reflects deteriorating market sentiment despite a strong 3-year return.

LGND presents a dichotomy between exceptional operational profitability and poor deterministic health/value scores. While the company boasts a massive 46.42% profit margin and strong revenue growth (39.4%), the Piotroski F-Score of 3/9 indicates weak financial trend momentum. The stock is trading at a significant premium to its Graham Number ($84.23) and Intrinsic Value ($42.91), suggesting the market is pricing in aggressive future growth. Bearish insider activity and a weak technical trend further temper the outlook despite strong analyst target prices.